Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biologic agents in experimental autoimmune uveitis.

Literature DB >> 23494482

Biologic agents in experimental autoimmune uveitis.

Gian Paolo Giuliari¹, Ama Sadaka, David M Hinkle.

Abstract

Experimental uveitis models were developed in an effort to elucidate the pathogenesis of human uveitis. The therapeutic effects of numerous anti-inflammatory agents including corticosteroids and immunomodulatory agents including biologic response modifiers have been investigated in both experimental and human uveitis. Monoclonal antibodies to tumor necrosis factor alpha and anti-interleukins, among others, demonstrate efficacy and are employed in the treatment of uveitis refractory to conventional immunomodulatory agents.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23494482 DOI： 10.1007/s10792-013-9756-0

Source DB: PubMed Journal: Int Ophthalmol ISSN： 0165-5701 Impact factor: 2.031

139 in total

Review 1. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258

2. Impact of IL-1 signalling on experimental uveitis and arthritis.

Authors: Stephen R Planck; April Woods; Jenna S Clowers; Martin J Nicklin; James T Rosenbaum; Holly L Rosenzweig
Journal: Ann Rheum Dis Date: 2012-01-20 Impact factor: 19.103

3. The dream of biologics in uveitis.

Authors: Annabelle A Okada
Journal: Arch Ophthalmol Date: 2010-05

4. Rodent models of experimental autoimmune uveitis.

Authors: Rajeev K Agarwal; Phyllis B Silver; Rachel R Caspi
Journal: Methods Mol Biol Date: 2012

5. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.

Authors: G Sartani; P B Silver; L V Rizzo; C C Chan; B Wiggert; G Mastorakos; R R Caspi
Journal: Invest Ophthalmol Vis Sci Date: 1996-10 Impact factor: 4.799

6. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats.

Authors: A A Okada; J Sakai; M Usui; J Mizuguchi
Journal: Ocul Immunol Inflamm Date: 1998-06 Impact factor: 3.070

7. Macrophages in the retina of normal Lewis rats and their dynamics after injection of lipopolysaccharide.

Authors: P Yang; A F de Vos; A Kijlstra
Journal: Invest Ophthalmol Vis Sci Date: 1996-01 Impact factor: 4.799

8. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.

Authors: Rene A Cervantes-Castañeda; Gian Paolo Giuliari; Michael J Gallagher; Taygan Yilmaz; Rebecca E MacDonell; Karina Quinones; Charles S Foster
Journal: Eur J Ophthalmol Date: 2009 Jul-Aug Impact factor: 2.597

9. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors: J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal: EMBO J Date: 1991-12 Impact factor: 11.598

10. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis.

Authors: F G Roberge; H Lorberboum-Galski; P Le Hoang; M de Smet; C C Chan; D Fitzgerald; I Pastan
Journal: J Immunol Date: 1989-12-01 Impact factor: 5.426

3 in total